Invited commentary: A future of data-rich pharmacoepidemiology studies- transitioning to large-scale linked EHR+claims data.

ABSTRACT

Electronic health record (EHR) data are seen as an important source for Pharmacoepidemiology studies. In the US healthcare system, EHR systems often only identify fragments of patients' health information across the care continuum, including primary care, specialist care, hospitalizations, and pharmacy dispensing. This leads to unobservable information in longitudinal evaluations of medication effects causing unmeasured confounding, misclassification, and truncated follow-up times. A remedy is to link EHR data with longitudinal claims data which record all encounters during a defined enrollment period across all care settings. We evaluate EHR and claims data sources in three aspects relevant to etiologic studies of medical products data continuity, data granularity, and data chronology. Reflecting on the strengths and limitations of EHR and insurance claims data, it becomes obvious that they complement each other. The combination of both will improve the validity of etiologic studies and expand the range of questions that can be answered. As the research community transitions towards a future state with access to large-scale combined EHR+claims data, we outline analytic templates to improve the validity and broaden the scope of pharmacoepidemiology studies in the current environment where EHR data are available only for a subset of patients with claims data.